Genetic Tumor Profiling Using Circulating Tumor DNA Analysis in Patients with Advanced Solid Tumors During Molecular Biology Meetings in Eastern PACA

What this Trial Is About

Researchers are evaluating the use of liquid biopsy to detect molecular abnormalities in patients with advanced malignant solid tumors who are managed through a Multidisciplinary Molecular Biology Meeting. The study aims to compare the diagnostic accuracy of liquid biopsy with the current gold standard, solid biopsy, to better understand its performance. This diagnostic study is sponsored by Centre Antoine Lacassagne and focuses on patients in a non-curative context. Participants will have a 36 mL blood sample taken for molecular analysis using liquid biopsy methods. This analysis will be conducted alongside routine molecular tests performed on archived tumor tissue solid biopsy or biopsiable tumor lesions. The study is designed as a single-group interventional trial where all participants undergo this blood sampling procedure. During the study, participants will provide consent, undergo blood sampling, and have their tumor samples analyzed. Researchers will measure the sensitivity and specificity of the liquid biopsy compared to the solid biopsy within one month, as well as assess failure rates, clinical factors affecting sensitivity, the rate of unexploitable results, and time needed to obtain each analysis. The study runs from March 2025 through June 2027, with results informing the diagnostic utility of liquid biopsy in this patient population.

Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA